Introduction
Salmonella enterica serovars Typhi and Paratyphi A, B and C are highly adapted, human-specific pathogens causing typhoid or enteric fever. Infections are systemic, characterized by fever and gastrointestinal symptoms, and associated with significant morbidity. Death can occur, especially if appropriate antimicrobial therapy is delayed. 1 Globally, there are 27 million cases of typhoid fever worldwide and .200000 attributable deaths per year, predominantly among children ,5 years old. 2 Typhoid fever is a significant public health problem throughout the developing world, with particularly high incidence in SouthEast Asia. 1, 3 In the developed world the incidence of typhoid fever has declined over the last century with the provision of clean water and good sanitation, and it is now predominantly a disease associated with travellers returning from high-risk regions. 4 For example, in the USA the annual incidence dropped from 7.5 per 100000 in 1940 to 0.2 per 100000 in the 1990s, whereas the incidence related to foreign travel increased from 33% in 1967-72 to 81% in 1996-97. 4 Between 2006 and 2011, PHE (formerly the HPA) reported 500 (range 457-520) cases of enteric fever per year. Since 2012, the number of cases has decreased, with 311 reports in 2014 and 286 in 2015 (https://www.gov.uk/government/publica tions/typhoid-and-paratyphoid-laboratory-confirmed-cases-in-en gland-wales-and-northern-ireland). In 2015, .90% of cases were acquired abroad, the majority from travellers returning to the UK from the Indian subcontinent. Travel to sub-Saharan Africa and South America was also documented (https://www.gov.uk/govern ment/uploads/system/uploads/attachment_data/file/618840/Ent eric_fever_annual_report_2015.pdf).
The advent of chloramphenicol treatment changed the perception of typhoid fever from a severe, often fatal, disease to a readily manageable infection. 4 However, outbreaks of chloramphenicolresistant Salmonella Typhi were reported as early as 1972 and by the 1990s outbreaks of typhoid caused by strains resistant to chloramphenicol, sulphonamides, trimethoprim and ampicillin were widespread. 5 Fluoroquinolones became the first-line antimicrobial therapy following their introduction in the 1980s and were initially associated with rapid fever clearance and low rates of both relapse and chronic faecal carriage. 4 However, reduced ciprofloxacin susceptibility (MIC 0.06-0.25 mg/L) has become increasingly prevalent in Salmonella Typhi and Salmonella Paratyphi and has been associated with clinical failure. 6, 7 Reduced ciprofloxacin susceptibility is not detected by standard ciprofloxacin disc diffusion testing. Nalidixic acid resistance has been used as a surrogate marker, but does not detect all cases. 8 In the UK, .90% of Salmonella Typhi and Salmonella Paratyphi isolates acquired in India between 2006 and 2007 were nalidixic acid resistant.
9
Alternative antimicrobials, including third-generation cephalosporins or azithromycin, are increasingly used as first-line therapies. 3 Reports of emergence of resistance to third-generation cephalosporins and azithromycin have raised concern amongst clinicians. 10, 11 In April 2014, PHE implemented WGS as the routine method of surveillance for Salmonella species. 12 Known genotypes associated with mechanisms of antimicrobial resistance (AMR) are detected and phenotypic AMR profiles can be inferred. 13 The aim of this study was to compare and evaluate phenotypic and genotypic methods for detection of AMR in Salmonella Typhi and Salmonella Paratyphi A, B and C.
Methods

Bacterial isolates
Phenotypic and genotypic testing was performed on 603 isolates of Salmonella Typhi (n " 332), Salmonella Paratyphi A (n " 227) and Salmonella Paratyphi B (n " 44) submitted to PHE between April 2014 and August 2016. No isolates of Salmonella Paratyphi C were submitted to PHE during this time frame. The isolates were from 527 patients reporting to general practitioners or local hospitals in the UK with diarrhoea, abdominal pain and/or symptoms consistent with typhoid fever (Salmonella Typhi patients, n " 292; Salmonella Paratyphi A patients, n " 197; Salmonella Paratyphi B patients, n " 38).
WGS
Following extraction at Containment Level 3, genomic DNA was fragmented and tagged for multiplexing with Nextera XT DNA Sample Preparation Kits, followed by paired-end sequencing on an Illumina HiSeq 2500 platform to produce 100 bp paired-end reads (Illumina, Cambridge, UK). AMR determinants were sought using Genefinder, a customized algorithm that uses Bowtie 2 to map reads to a set of reference sequences and Samtools to generate an mpileup file.
14 The data are parsed based on read coverage of the query sequence (100%), consensus base-call variation (.85%) and nucleotide identity (.90%) to determine the presence of the reference sequence or nucleotide variation within that sequence. bLactamase variants were determined with 100% identity using the reference sequences downloaded from the Lahey (www.lahey.org) or NCBI (https://www.ncbi.nlm.nih.gov/pathogens/beta-lactamase-data-resources) b-lactamase data resources. Known acquired resistance genes and resistance-conferring mutations relevant to b-lactams (including carbapenems), fluoroquinolones, aminoglycosides, chloramphenicol, macrolides, sulphonamides, tetracyclines, trimethoprim, rifamycins and fosfomycin and acquired genes associated with colistin resistance were included in the analysis. 15, 16 Reference sequences for acquired resistance genes were curated from those described in the Comprehensive Antimicrobial Resistance Database (http://arpcard.mcmaster.ca) and the ResFinder datasets (https://cge.cbs. dtu.dk/services/data.php). Chromosomal mutations focused on previously published variations in the QRDRs of gyrA, gyrB, parC and parE, which are associated with resistance to quinolones, and in rpoB for rifampicin resistance. FASTQ sequences were deposited in the National Center for Biotechnology Information Short Read Archive (SRA) under the BioProject PRJNA315192 and the SRA numbers are available in Table S1 (available as Supplementary data at JAC Online).
ST, eBurst Group (eBG) and serotype were determined from the genome data using MOST. 17, 18 Antimicrobial susceptibility testing Susceptibility testing was performed retrospectively on all isolates recovered from the PHE archive. MICs were determined in Containment Level 3 by agar dilution using Mueller-Hinton agar for the following antimicrobials: ampicillin, nalidixic acid, ciprofloxacin, streptomycin, gentamycin, trimethoprim, tetracycline, sulphonamides, chloramphenicol, rifampicin, fosfomycin and azithromycin. Breakpoints and screening concentration criteria used for interpretation were as recommended by EUCAST (http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/ Breakpoint_tables/v_7.1_Breakpoint_Tables.pdf). Confirmation of MICs of azithromycin, trimethoprim, chloramphenicol and streptomycin was undertaken by Etest V R (bioMérieux, France). Temocillin and cefoxitin were included in the panel to aid detection of OXA-48-like carbapenemases and AmpC production, respectively.
Results
Of the 527 patients in this study, 242 (45.9%) were female, 283 (53.7%) were male and gender information was not provided for two cases. A travel history was provided for 486 (92.2%) of the 527 cases, with 442 (83.9%) reporting travel within 14 days of onset of symptoms and 44 (8.3%) reporting no travel in that time frame. No travel history was available for 41 (7.8%) cases. The most frequently reported travel destinations from patients with Salmonella Typhi and Salmonella Paratyphi A infection were India (Salmonella Typhi, n " 108; Salmonella Paratyphi A, n " 81), Pakistan (Salmonella Typhi, n " 72; Salmonella Paratyphi A, n " 52) and Bangladesh (Salmonella Typhi, n " 20; Salmonella Paratyphi A, n " 16). Peru (n " 9) and Iraq (n " 7) were the most frequently reported travel destinations from patients with Paratyphi B.
Of the 603 isolates from these cases, 358 (59.4%) were from blood cultures (Salmonella Typhi, n " 197; Salmonella Paratyphi A, n " 141; Salmonella Paratyphi B, n " 20), 181 (30.0%) were from faeces (Salmonella Typhi, n " 93; Salmonella Paratyphi A, n " 67; Salmonella Paratyphi B, n " 21) and the infection site was not stated for the remaining 64 (10.6%) (Salmonella Typhi, n " 42; Salmonella Paratyphi A, n " 19; Salmonella Paratyphi B, n " 3). The isolates of Salmonella Typhi belonged to eBG 13 (ST1, n " 243; ST2, n " 89), Salmonella Paratyphi A were eBG 11 (ST85, n " 128; ST129, n " 97; ST1938, n " 1; ST1929, n " 1) and Salmonella Paratyphi B were eBG 5 (ST86, n " 44).
Comparison between phenotypic and genotypic AMR
The phenotypic and genotypic AMR results showed high concordance, with 601 (99.7%) of 603 isolates having identical categorical Day et al. agreement across their complete susceptibility profile, which included 10 classes of antimicrobials. The two isolates exhibiting a discrepancy each had a mismatch for only one antimicrobial; therefore there were only 2 (0.03%) discordant results out of a possible 6030 isolate/antimicrobial class combinations. One isolate was phenotypically resistant to streptomycin (MIC .32 mg/L), but no corresponding resistance determinant was detected in the genome (Table 1) . One isolate was predicted to be resistant to sulphonamides from the genome-derived data (sul1 detected), but was phenotypically susceptible (MIC ,16 mg/L) ( Table 1 ).
Resistance to b-lactams, aminoglycosides, sulphonamides, trimethoprim, tetracyclines and phenicols in Salmonella Typhi
Of the 332 isolates of Salmonella Typhi, 77 (23.2%) had bla TEM-1 , predicted to confer resistance to ampicillin (Table 2) . No other b-lactamase genes were detected in any of the isolates. Seventy-six (22.9%) isolates had genes predicted to confer streptomycin resistance, all of which had strA-strB. No phenotypic or genotypic resistance to gentamicin and tobramycin was detected and there were no 16S rRNA methyltransferase genes identified.
Eighty-two (24.7%) isolates had dfrA alleles (dfrA1, n " 1; dfrA7, n " 74; dfrA14, n " 1; dfrA15, n " 6), conferring resistance to trimethoprim (Table 2) .
Eighty-three (25.0%) isolates had genes predicted to confer sulphonamide resistance, of which 7 (8.4%) had sul1, 2 (2.4%) had sul2 and 74 (89.2%) had both sul1 and sul2 (Table 2) .
Six (1.8%) isolates had tetA(A) ( Table 2 ) and no other tetracycline resistance determinants were detected.
Seventy-nine (23.8%) isolates had catA1, predicted to confer chloramphenicol resistance (Table 2 ).
Resistance to quinolones in Salmonella Typhi
Of the 332 isolates of Salmonella Typhi in this study, 36 (Tables 2 and 3) .
A plasmid-mediated quinolone resistance (PMQR) determinant, qnrB19, was detected in just one isolate, in combination with a gyrA[83:S-F] mutation.
Resistance to macrolides, rifamycins, fosfomycin and colistin in Salmonella Typhi
None of the isolates was predicted to be resistant to the macrolides, rifamycins or fosfomycin and no acquired genes associated with colistin resistance were detected. No genotypic or phenotypic resistance was detected in Salmonella Paratyphi A to b-lactams, aminoglycosides, macrolides, sulphonamides, chloramphenicol or trimethoprim. 
Resistance profiles in Salmonella Paratyphi
MDR profiles
Based on the WGS prediction, 292/332 (88.0%) isolates of Salmonella Typhi were resistant (or had reduced susceptibility) to at least one antimicrobial on the panel tested, compared with 209/227 (92.1%) Salmonella Paratyphi A and 6/44 (13.6%) Salmonella Paratyphi B.
Eighty-three (13.8%) of the 603 isolates were MDR (i.e. resistant to three or more classes of antimicrobials) ( Table 4) . 19 All 83 isolates were Salmonella Typhi, representing 25.0% of the 332 isolates of Salmonella Typhi tested. The most common genotypic resistance profiles for Salmonella Typhi were: (i) gyrA[83:S-F] (n " 106); (ii) gyrA[83:S-F]/bla TEM-1 /strA-strB/dfrA7/sul1:sul2/catA1 
Discussion
A comparison of the phenotypic and genotypic resistance profiles for a large collection of typhoidal salmonellae identified only 2 (0.03%) discordant results out of a possible 6030 isolate/antimicrobial combinations. One isolate had sul1, but was phenotypically susceptible to the sulphonamides (MIC ,16 mg/L), indicating that the AMR determinant was present but expression was reduced. A second isolate was phenotypically resistant to streptomycin (MIC .32 mg/L), but no streptomycin resistance determinants were detected in the genome.
Previous studies have shown that deriving AMR profiles from the genome data is a robust and accurate approach. 13, 15, 16, [20] [21] [22] However, there is a risk of missing novel resistance mechanisms not included in the reference database, which would result in predicting susceptibility for a phenotypically resistant isolate. This is classed as a 'very major error' as it could potentially mean that a patient would be given ineffective treatment. Regular updating of the database to include novel AMR genes and mutations is essential to ensure the ongoing accuracy of AMR profiles derived from WGS data. 23 Resistance to ampicillin, streptomycin, sulphonamides, trimethoprim and chloramphenicol was detected in 23.2%, 22.9%, 25.0%, 24.7% and 23.8% of isolates of Salmonella Typhi, respectively, with 22.9% of isolates exhibiting resistance to all five antimicrobials. Using WGS, Wong et al. 24 (2015) identified a single dominant MDR lineage of Salmonella Typhi that had emerged and spread throughout Asia and Africa over the last 30 years, displacing antibiotic-susceptible isolates. In this lineage, MDR was mediated either via transmissible IncHI1 plasmids or within multiple chromosomal integration sites corresponding with the loss of the tetA(A) determinant encoding resistance to tetracycline. 24 In our study, 6 isolates had tetA(A) and a varied combination of bla TEM-1 , strA-strB, sul1, sul2, dfrA15 and catA1, whereas 77 isolates exhibited a varied combination of bla TEM-1 , strA-strB, sul1, sul2, dfrA and catA1 without tetA(A).
The increasing incidence of MDR Salmonella Typhi globally during the 1990s prompted an increase in the use of fluoroquinolones for the treatment of enteric fever in the UK and elsewhere. 3, 4, 25 It has been suggested that this change has caused the progressive re-emergence of susceptibility to traditional first-line drugs. 4, 26, 27 Nevertheless, in the UK, the incidence of resistance to ampicillin, streptomycin, sulphonamides, trimethoprim and chloramphenicol has remained stable over the last decade, at around 22%-23%. 25, 28 The introduction of fluoroquinolones in the 1990s led to an increase in the numbers of isolates that were resistant to nalidixic acid and exhibited reduced susceptibility to ciprofloxacin. 6, 29, 30 Such isolates were susceptible to ciprofloxacin by disc testing, but were associated with clinical failure. 7, 31 Single point mutations, identified in gyrA of Salmonella Typhi and Salmonella Paratyphi A, were associated with reduced susceptibility to ciprofloxacin. 32, 33 In this study, comparisons with historical data in England and Wales were confounded by the lack of standardized testing prior to 2014. A local hospital study in England spanning the years 1990-2009 demonstrated a dramatic increase in reduced susceptibility and resistance to ciprofloxacin in both Salmonella Typhi and Salmonella WGS prediction of resistance in Salmonella Typhi and Paratyphi
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Paratyphi A during this period. 28 This was supported by data produced at the national reference laboratory. 9, 25 In the dataset described here, the parC[57:T-S] mutation was identified in all isolates of Salmonella Paratyphi A and there is evidence that, when present with no additional mutations in the DNA gyrase or topoisomerase genes, this mutation does not confer reduced susceptibility. 34 However, a combination of a single mutation in gyrA and parC[57:T-S] in Salmonella Paratyphi A appears to be associated with full resistance to ciprofloxacin (MIC .0.5 mg/L). (Table 3) . These findings are consistent with previous studies showing increasing MIC associated with a Day et al.
higher number of mutations. 36, 37 A single mutation in gyrB in Salmonella Typhi associated with reduced susceptibility to ciprofloxacin has been described previously. 38 There is clinical evidence that treatment with ciprofloxacin may be associated with a poor response in systemic infections caused by Salmonella spp. with reduced susceptibility to ciprofloxacin (MIC .0.06 mg/L). The available data relate mainly to Salmonella Typhi, but there are case reports of poor response with other Salmonella species (http://www. eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/ v_7.1_Breakpoint_Tables.pdf).
PMQR genes in Salmonella Typhi and Salmonella Paratyphi A and B did not confer reduced susceptibility to ciprofloxacin (MIC .0.06 mg/L) unless they co-existed with gyrA QRDR mutations. To avoid missing PMQR determinants, EUCAST recommends the use of perfloxacin discs, which reliably detect all forms of quinolone resistance except resistance caused by aac(6 0 )-Ib-cr. 39 In our study, WGS data showed that PMQR determinants were rarely detected in either Salmonella Typhi or Salmonella Paratyphi.
Although published evidence does not yet support the use of WGS-inferred antimicrobial susceptibility to guide clinical decision making for infections caused by many bacterial species, 40 this study and others have shown that analysis of WGS data is a robust and informative approach to monitoring MDR and emerging resistance to ciprofloxacin in Salmonella Typhi. 41, 42 The current trend of AMR seen in imported cases of enteric fever from across the world returning to the UK supports the empirical use of third-generation cephalosporins and/or azithromycin until results of phenotypic susceptibility testing are available. Phenotypic antimicrobial susceptibility testing continues to be performed to guide patient treatment, but inferring AMR profiles from WGS data is appropriate for surveillance to guide empirical therapy.
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